IGWM
LRMR icon

ICA Group Wealth Management’s Larimar Therapeutics LRMR Stock Holding History

ICA Group Wealth Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75
Closed -$569 – 1083
2024
Q1 		$569 Buy
+75
New +$584 ﹤0.01% 1290

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ICA Group Wealth Management's LRMR Position: Q2 2024 in Review

ICA Group Wealth Management sold out of Larimar Therapeutics (LRMR) in Q2 2024, closing a stake of 75 shares — an estimated $569 sold.

ICA Group Wealth Management first reported a position in LRMR in Q1 2024 and held it in 1 quarter. The position peaked at $569 in Q1 2024. 106 funds tracked by Wall St. Rank hold LRMR as of Q2 2024.

  • ICA Group Wealth Management reported no remaining Larimar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ICA Group Wealth Management sold 75 Larimar Therapeutics shares in Q2 2024, an estimated $569.
  • ICA Group Wealth Management first reported a position in Larimar Therapeutics in Q1 2024 and held it in 1 quarter.
  • ICA Group Wealth Management's Larimar Therapeutics position peaked at $569 in Q1 2024.
  • 106 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.